Does the Underlying Haemodynamic Abnormality Determine Response to Antihypertensive Therapy.

Trial Profile

Does the Underlying Haemodynamic Abnormality Determine Response to Antihypertensive Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Bisoprolol (Primary) ; Candesartan cilexetil (Primary) ; Doxazosin (Primary) ; Isosorbide mononitrate (Primary)
  • Indications Cardiovascular disorders; Hypertension
  • Focus Therapeutic Use
  • Acronyms ROTATION
  • Most Recent Events

    • 31 May 2012 United Kingdom Clinical Research Network reports accrual to date changed from 20% to 23%.
    • 31 May 2012 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top